Publications by authors named "M Hew"
Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma.
J Allergy Clin Immunol Pract
November 2024
Background: Mepolizumab can induce an early response and clinical remission in people with severe eosinophilic asthma (SEA).
Objective: To find whether early response to mepolizumab (100 mg) could predict future asthma remission and to identify the best predictor of treatment response to mepolizumab for achieving remission.
Methods: The Australian Mepolizumab Registry was used to investigate the early response to mepolizumab at 3 and 6 months and relate this to clinical remission at 12 months.
Medication use in people with cystic fibrosis before and after modulator therapy.
Pulm Pharmacol Ther
October 2023
Background: Long-term changes in medication dispensings post cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation have not been described. Our study aimed to investigate changes in medication use following the initiation of modulator therapy in people with cystic fibrosis (PwCF) in Australia.
Methods: Using a 10% sample of the Australian Pharmaceutical Benefits Scheme (PBS) data between 2013 and 2022, linear regression was used to analyse dispensings in PwCF who initiated any modulator (cases) and matched PwCF controls not dispensed a modulator.
Article Synopsis
- Abnormal breathlessness during intense exercise can result from several conditions like exercise-induced bronchospasm, laryngeal obstruction, or breathing pattern disorders, often missed in regular tests.
- A retrospective study involved 24 patients, including professional athletes, where advanced testing revealed specific conditions in 66.7% of cases, leading to tailored treatment plans.
- Significant findings included that 38% had exercise-induced laryngeal obstruction, predominantly in younger athletes, and highlighted the need for specialized follow-up and interventions based on individual diagnoses.